GNOMX Corp.

Next-generation epigenetic / AI diagnostic platform for infectious disease

health AIdiagnosticsinfectious disease

Visit website

StageSpin-off, BARDA-funded contract recipient

Raised$749,700

Founded2022

Employees2

LocationNew York, NY

About

GNOMX was founded to commercialize host response epigenetic diagnostics based on research funded by a $46 million DARPA ECHO contract to an academic consortium led by the Icahn School of Medicine at Mount Sinai, Yale University School of Medicine, Princeton University, and the University of Pittsburgh School of Medicine. The DARPA-sponsored research developed patent-pending, beyond state-of-the-art blood epigenetic tests that rapidly diagnose, determine time of exposure, and monitor long-term effect of infections and other exposures.

Founders

J. Mark Junewicz — Co-founder and CEO
Stuart C. Sealfon, MD — Co-founder, CSO and SAB Chair

Products

epigenetic/AI diagnostic platform for infectious disease

Key features

epigenetic profilingAI-powered diagnosticspredictive analytics for infectious diseasesBARDA DRIVe awarded contract (readmission prediction)

Technologies

epigeneticsAI/MLdiagnostic platformpredictive analytics

Target conditions

infectious diseasessepsisdiagnostic outcomes

Care settings

clinicalhospitallaboratoryresearch

Notable customers

BARDA DRIVe contract for sepsis patient readmission prediction

Awards

BARDA DRIVe contract award

Traction metrics

Investors

Mount Sinai Health System

News

J. Mark Junewicz - Co-founder and CEO of GNOMX Corp... - LinkedIn · 2025-12-15T00:00:00.000Z
MSIP Recognizes Researchers at Annual Innovation Awards Ceremony - Mount Sinai Innovation Partners · 2024-11-05T19:23:48.000Z
News - Mount Sinai Innovation Partners · 2025-01-09T00:00:00.000Z
Cancer Diagnostics Startup Imagenomix Raises $3.2M in Seed Funding | GenomeWeb · 2026-05-07T17:43:13.000Z
CEO Welcome Message - Genome X · 2024-07-26T06:55:04.000Z